Oric(US:ORIC)2025-11-13 21:15Financial Position - ORIC Pharmaceuticals reported cash and investments of approximately $413 million, expected to fund operations into the second half of 2028[1]. - The company raised $108.7 million in net proceeds under the at-the-market (ATM) program during Q3 2025[7]. Research and Development - Research and development (R&D) expenses for Q3 2025 were $28.8 million, a decrease of 7.7% from $31.2 million in Q3 2024[10]. - Research and development expenses for Q3 2025 were $28.773 million, a decrease from $31.202 million in Q3 2024, while year-to-date R&D expenses increased to $83.962 million from $82.102 million[18]. - ORIC anticipates reporting four clinical data readouts across ORIC-944 and enozertinib programs through mid-2026[1]. - ORIC-944 demonstrated a 55% PSA50 response rate and a 20% PSA90 response rate in a Phase 1b trial involving 20 patients with metastatic castration-resistant prostate cancer[6]. - 76% of patients in the ORIC-944 trial achieved over 50% reduction in circulating tumor DNA (ctDNA), with 59% achieving ctDNA clearance[6]. - ORIC-944 is being developed in combination with darolutamide and apalutamide, with recommended Phase 2 doses set at 400 mg and 600 mg once daily[3]. - Enozertinib is expected to present data at ESMO Asia 2025 in December 2025, focusing on multiple patient cohorts[10]. Operating Expenses - General and administrative (G&A) expenses for Q3 2025 were $7.9 million, an increase of 11.3% from $7.1 million in Q3 2024[10]. - General and administrative expenses rose to $7.898 million in Q3 2025 compared to $7.116 million in Q3 2024, with year-to-date expenses increasing to $24.491 million from $21.223 million[18]. - Total operating expenses for Q3 2025 were $36.671 million, down from $38.318 million in Q3 2024, while year-to-date total operating expenses increased to $108.453 million from $103.325 million[18]. Net Loss and Income - The net loss for Q3 2025 was $32.587 million, slightly improved from a net loss of $34.566 million in Q3 2024, with year-to-date net loss increasing to $98.963 million from $91.540 million[18]. - The comprehensive loss for Q3 2025 was $32.159 million, compared to $33.588 million in Q3 2024, with year-to-date comprehensive loss at $98.727 million versus $91.076 million[18]. - Basic and diluted net loss per share for Q3 2025 was $0.33, an improvement from $0.49 in Q3 2024, while year-to-date loss per share decreased to $1.20 from $1.32[18]. - Other income for Q3 2025 was $4.084 million, an increase from $3.752 million in Q3 2024, with year-to-date other income decreasing to $9.490 million from $11.785 million[18]. Share Information - The weighted-average shares outstanding for Q3 2025 were 98,953,331, compared to 70,542,684 in Q3 2024, and year-to-date shares increased to 82,808,969 from 69,417,672[18]. Management Changes - The company appointed Kevin Brodbeck, PhD, as Chief Technical Officer to support late-stage development[5].